The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?

Journal of the Royal Society of Medicine

Volumn 102, Issue 5, 2009, Pages 186-194

  Howick, Jeremy ^a   Glasziou, Paul ^a   Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG MECHANISM; EVIDENCE BASED PRACTICE; HUMAN; LUNG CANCER; MOUTH ULCER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 66749086365     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2009.090020     Document Type: Review

References (51)

1. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94
2. Keen HI, Pile K, Hill CL. The prevalence of underpowered randomized clinical trials in rheumatology. J Rheumatol 2005;32:2083-8
3. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ 2004;328:432
4. Hrobjartsson A, Forfang E, Haahr MT, Als-Nielsen B, Brorson S. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 2007;36:654-63
5. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007;334:349-51
6. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003;327:1459-61
7. Harbour RT, ed. SIGN 50: A guideline developer's handbook. Edinburgh: NHS Quality Improvement Scotland; 2008
8. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Oxford: CEBM; 2001. See http://www.cebm.net/ index.aspx?0=1025 (accessed 30 January 2009)
9. Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ 1979;121:1193-254
10. US Preventive Services Task Force. Guide to Clinical Preventive Services. Washington, DC: US Department of Health and Human Services; 1996
11. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490
12. Atkins D, Briss PA, Eccles M, et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005;5:25
13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6
14. Shang A, Huwiler-Muntener K, Nartey L, et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet 2005;366:726-32
15. Williamson J, Russo F. Interpreting Causality in the Health Sciences. Int Stud Philos Sci 2007;21:157-70
16. Marshall T. Bradford-Hill Criteria provide the way ahead for controversial theory. Int J Surg 2005;3:287-8
17. Perrio M, Voss S, Shakir SA. Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf 2007;30:333-46
18. Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 2002;25:467-71
19. Staudenmayer H, Binkley KE, Leznoff A, Phillips S. Idiopathic environmental intolerance: Part 2: A causation analysis applying Bradford Hill's criteria to the psychogenic theory. Toxicol Rev 2003;22:247-61
20. Staudenmayer H, Binkley KE, Leznoff A, Phillips S. Idiopathic environmental intolerance: Part 1: A causation analysis applying Bradford Hill's criteria to the toxicogenic theory. Toxicol Rev 2003;22:235-46
21. van Reekum R, Streiner DL, Conn DK. Applying Bradford Hill's criteria for causation to neuropsychiatry: challenges and opportunities. J Neuropsychiatry 2001;13:318-25
22. Hill ABS, Hill ID. Bradford Hill's principles of medical statistics. 12th edn. Edinburgh: Edward Arnold; 1991
23. Hill AB. The Environment and Disease: Association or Causation? Proc Roy Soc Med 1965;58:295-300
24. Phillips CV, Goodman KJ. The missed lessons of Sir Austin Bradford Hill. Epidemiol Perspect Innov 2004;1:3
25. Concato J. Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx 2004;1:341-7
26. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
27. Wood L, Egger M, Gluud L, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5
28. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005;3:449-56
29. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743-56
30. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34
31. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004;1:CD003012
32. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341- 5
33. Barbui C, Cipriani A. Publication bias in systematic reviews. Arch Gen Psychiatry 2007;64:868
34. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005;162:1957-60
35. Procopio M. The multiple outcomes bias in antidepressants research. Med Hypotheses 2005;65:395-9
36. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519
37. Cartwright N. Hunting causes and using them: approaches in philosophy and economics. Cambridge: Cambridge University Press; 2007
38. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. BMJ 1954;1:1451-5
39. Machamer P, Darden L, Craver CF. Thinking About Mechanisms. Philos Sci 2000;67:1-25
40. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-60
41. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8
42. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-92
43. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22
44. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17
45. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
46. Spock B, Fox D. Baby and Child Care. New York, NY: Pocket Books; 1966
47. Gillies D. Hempelian and Kuhnian approaches in the philosophy of medicine: the Semmelweis case. Stud Hist Philos Sci C Stud Hist Biol Biomed Sci 2005;36:159-81
48. Marshall B. Helicobacter connections. Chem Med Chem 2006;1:783-802
49. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006;333:1267-9
50. Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ 2003;327:616-18
51. Aronson JK. Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. J Eval Clin Pract 2005;11:195-208